EPIRUS Biopharmaceuticals Overview
- Year Founded
-
2000
- Status
-
Out of Business
- Employees
-
51
- Latest Deal Type
-
Out of Business
EPIRUS Biopharmaceuticals General Information
Description
Operator of a biopharmaceutical company developing biosimilar monoclonal antibodies. The company's platform is focused on building a biosimilar business targeting rare diseases by improving patient access through cost-effective medicines, and the company is researching BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman's disease, providing the medical industry with research materials on different types of treatments.
Contact Information
Website
www.epirusbiopharma.comCorporate Office
- 699 Boylston Street
- 11th Floor
- Boston, MA 02116
- United States
Corporate Office
- 699 Boylston Street
- 11th Floor
- Boston, MA 02116
- United States
EPIRUS Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 24-Oct-2025 | Completed | Out of Business | |||
| 5. Bankruptcy: Liquidation | 25-Jul-2016 | Completed | Bankruptcy: Liquidation | |||
| 4. Debt - General | 31-Dec-2014 | Completed | Profitable | |||
| 3. Reverse Merger | 15-Jul-2014 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series B) | 16-Apr-2014 | $36M | $74M | Completed | Clinical Trials - Phase 2 | |
| 1. Later Stage VC (Series A) | 24-Jan-2011 | $38M | $38M | Completed | Product Development |
EPIRUS Biopharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
EPIRUS Biopharmaceuticals Comparisons
Industry
Financing
Details
EPIRUS Biopharmaceuticals Competitors (39)
One of EPIRUS Biopharmaceuticals’s 39 competitors is BeOne Medicines, a Formerly PE-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain |
EPIRUS Biopharmaceuticals Patents
EPIRUS Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2940897-A1 | Heterocyclic inhibitors of the sodium channel | Inactive | 27-Feb-2014 | ||
| EP-3110799-A1 | Heterocyclic inhibitors of the sodium channel | Inactive | 27-Feb-2014 | ||
| EP-3110799-A4 | Heterocyclic inhibitors of the sodium channel | Inactive | 27-Feb-2014 | ||
| US-20170107203-A1 | Heterocyclic inhibitors of the sodium channel | Inactive | 27-Feb-2014 | ||
| US-20170145003-A1 | Heterocyclic inhibitors of the sodium channel | Inactive | 27-Feb-2014 | C07D417/12 |
EPIRUS Biopharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EPIRUS Biopharmaceuticals Acquisitions (1)
EPIRUS Biopharmaceuticals’s most recent deal was a Merger/Acquisition with Bioceros for . The deal was made on 09-Sep-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bioceros | 09-Sep-2015 | Merger/Acquisition | Drug Discovery |
EPIRUS Biopharmaceuticals FAQs
-
When was EPIRUS Biopharmaceuticals founded?
EPIRUS Biopharmaceuticals was founded in 2000.
-
Where is EPIRUS Biopharmaceuticals headquartered?
EPIRUS Biopharmaceuticals is headquartered in Boston, MA.
-
What is the size of EPIRUS Biopharmaceuticals?
EPIRUS Biopharmaceuticals has 51 total employees.
-
What industry is EPIRUS Biopharmaceuticals in?
EPIRUS Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is EPIRUS Biopharmaceuticals a private or public company?
EPIRUS Biopharmaceuticals is a Private company.
-
What is EPIRUS Biopharmaceuticals’s current revenue?
The current revenue for EPIRUS Biopharmaceuticals is .
-
How much funding has EPIRUS Biopharmaceuticals raised over time?
EPIRUS Biopharmaceuticals has raised $81.5M.
-
Who are EPIRUS Biopharmaceuticals’s competitors?
BeOne Medicines, Merck & Co., Genentech, Sorrento Therapeutics, and Ability Pharma are some of the 39 competitors of EPIRUS Biopharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
